CU24732B1 - Mezcla de compuestos con altos pesos moleculares, obtenida a partir de la cera de caña de azúcar (saccharum officinarum l.) - Google Patents

Mezcla de compuestos con altos pesos moleculares, obtenida a partir de la cera de caña de azúcar (saccharum officinarum l.)

Info

Publication number
CU24732B1
CU24732B1 CU2021000060A CU20210060A CU24732B1 CU 24732 B1 CU24732 B1 CU 24732B1 CU 2021000060 A CU2021000060 A CU 2021000060A CU 20210060 A CU20210060 A CU 20210060A CU 24732 B1 CU24732 B1 CU 24732B1
Authority
CU
Cuba
Prior art keywords
high molecular
compounds
mixture
revealed
sugar cane
Prior art date
Application number
CU2021000060A
Other languages
English (en)
Other versions
CU20210060A7 (es
Inventor
Canavaciolo Víctor Luis González
Castaño Sarahí Mendoza
Cuevas Vivian Molina
González Laura Salahange
Murillo Roxana Vicente
Original Assignee
Centro Nac De Investigaciones Cientificas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Nac De Investigaciones Cientificas filed Critical Centro Nac De Investigaciones Cientificas
Priority to CU2021000060A priority Critical patent/CU24732B1/es
Priority to JP2024501681A priority patent/JP2024525717A/ja
Priority to PCT/CU2022/050005 priority patent/WO2023284902A1/es
Priority to CN202280048678.XA priority patent/CN117979984A/zh
Priority to US18/576,577 priority patent/US20240327748A1/en
Priority to KR1020247004566A priority patent/KR20240046718A/ko
Priority to EP22841535.2A priority patent/EP4371566A4/en
Priority to CA3224592A priority patent/CA3224592A1/en
Priority to AU2022309928A priority patent/AU2022309928B2/en
Publication of CU20210060A7 publication Critical patent/CU20210060A7/es
Publication of CU24732B1 publication Critical patent/CU24732B1/es
Priority to JP2025165209A priority patent/JP2026004429A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B1/00—Production of fats or fatty oils from raw materials
    • C11B1/10—Production of fats or fatty oils from raw materials by extracting
    • C11B1/104—Production of fats or fatty oils from raw materials by extracting using super critical gases or vapours
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se revela una mezcla de compuestos con altos pesos moleculares, la cual presenta efectos neuroprotectores, al inhibir el déficit neurológico, lo que conduce a una mejoría en la sintomatología clínica, una reducción significativa de la muerte neuronal y por ende de la mortalidad. Además, presenta efectos antioxidantes que contribuyen a sustentar su eficacia neuroprotectora. Se revelan también composiciones para dosificación oral, con dicha mezcla de compuestos como ingrediente activo, las que pueden ser empleadas como composiciones nutricionales o farmacéuticas para el manejo de condiciones médicas relacionadas con el sistema nervioso central, particularmente enfermedades neurodegenerativas que involucran el deterioro y muerte neuronal. Las sustancias que componen este nuevo ingrediente activo son ácidos grasos entre 26 y 36 átomos de carbono en forma de sales alcalinas o alcalinotérreas, alcoholes grasos entre 24 y 34 átomos de carbono y aldehídos de alto peso molecular, extraídos y purificados a partir de la cera de la caña de azúcar (<em>Saccharum officinarum L</em>.). La combinación de estos tres grupos de sustancias de alto peso molecular, en la proporción específica que revela la presente invención, permite que ocurra un efecto sinérgico, el cual garantiza el efecto farmacológico deseado.</p>
CU2021000060A 2021-07-13 2021-07-13 Mezcla de compuestos con altos pesos moleculares, obtenida a partir de la cera de caña de azúcar (saccharum officinarum l.) CU24732B1 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CU2021000060A CU24732B1 (es) 2021-07-13 2021-07-13 Mezcla de compuestos con altos pesos moleculares, obtenida a partir de la cera de caña de azúcar (saccharum officinarum l.)
KR1020247004566A KR20240046718A (ko) 2021-07-13 2022-05-23 사탕수수 왁스(사카룸 오피시나룸 l.)로부터 수득된, 고분자량 화합물의 혼합물
PCT/CU2022/050005 WO2023284902A1 (es) 2021-07-13 2022-05-23 Mezcla de compuestos con altos pesos moleculares, obtenida a partir de la cera de caña de azúcar (saccharum officinarum l.)
CN202280048678.XA CN117979984A (zh) 2021-07-13 2022-05-23 从甘蔗蜡获得的具有高分子量的化合物的混合物
US18/576,577 US20240327748A1 (en) 2021-07-13 2022-05-23 Mixture of compounds with high molecular weights, obtained from sugar cane wax (saccharum officinarum l.)
JP2024501681A JP2024525717A (ja) 2021-07-13 2022-05-23 シュガーケンワックス（ＳＵＧＡＲＣＡＮＥ ＷＡＸ）（サトウキビ：Ｓａｃｃｈａｒｕｍ ｏｆｆｉｃｉｎａｒｕｍ Ｌ．）から得られる高分子量化合物の混合物
EP22841535.2A EP4371566A4 (en) 2021-07-13 2022-05-23 MIXTURE OF HIGH MOLECULAR WEIGHT COMPOUNDS FROM SUGARCANE WAX (SACCHARUM OFFICINARUM L.)
CA3224592A CA3224592A1 (en) 2021-07-13 2022-05-23 Mixture of compounds with high molecular weights, obtained from sugar cane wax (saccharum officinarum l.)
AU2022309928A AU2022309928B2 (en) 2021-07-13 2022-05-23 Mixture of compounds with high molecular weights, obtained from sugar cane wax (saccharum officinarum l.)
JP2025165209A JP2026004429A (ja) 2021-07-13 2025-10-01 シュガーケンワックス（ＳＵＧＡＲＣＡＮＥ ＷＡＸ）（サトウキビ：Ｓａｃｃｈａｒｕｍ ｏｆｆｉｃｉｎａｒｕｍ Ｌ．）から得られる高分子量化合物の混合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2021000060A CU24732B1 (es) 2021-07-13 2021-07-13 Mezcla de compuestos con altos pesos moleculares, obtenida a partir de la cera de caña de azúcar (saccharum officinarum l.)

Publications (2)

Publication Number Publication Date
CU20210060A7 CU20210060A7 (es) 2023-02-13
CU24732B1 true CU24732B1 (es) 2025-02-07

Family

ID=84919910

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000060A CU24732B1 (es) 2021-07-13 2021-07-13 Mezcla de compuestos con altos pesos moleculares, obtenida a partir de la cera de caña de azúcar (saccharum officinarum l.)

Country Status (9)

Country Link
US (1) US20240327748A1 (es)
EP (1) EP4371566A4 (es)
JP (2) JP2024525717A (es)
KR (1) KR20240046718A (es)
CN (1) CN117979984A (es)
AU (1) AU2022309928B2 (es)
CA (1) CA3224592A1 (es)
CU (1) CU24732B1 (es)
WO (1) WO2023284902A1 (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22225A1 (es) * 1990-11-30 1995-01-31 Cent Nac Investig Scient Composicion farmacautica que contiene mezcla de alcoholes alifaticos primarios superiores para el tratamiento de hipercolesterolemia y la hiperlipoproteinemia tipo ii asi como estimulante de la conducta sexual en animales y humanos
CU22229A1 (es) 1992-09-29 1996-01-31 Dalmer Lab Sa Policosanol, una mezcla de alcoholes alifaticos primarios superiores para hipergregabilidad plaquetaria, los accidentes isquemicos, trombosis e incluso efectividad contra ulceras gastricas quimicamente inducidas y su proceso de obtencion de la caña de azucar. el tratamiento de complicaciones ateroscleroticas tales como la
CN1030763C (zh) * 1992-01-15 1996-01-24 国家科学研究中心 由甘蔗蜡中制得高级脂族醇混合物的方法
CU22723A1 (es) * 1997-04-02 2002-02-28 Dalmer Lab Sa Mezcla de ácidos grasos primarios de alto peso molecular obtenidos de la cera de cana de azúcar y sus usos farmacéuticos
AUPO605097A0 (en) * 1997-04-07 1997-05-01 James Cook University Of North Queensland Food grade wax and process for preparing same
US20040076732A1 (en) * 1997-04-07 2004-04-22 James Cook University Food grade wax and process for preparing same
CA2270795A1 (en) 1999-05-05 2000-11-05 Gestilab Inc. Neuroprotective compositions and uses thereof
US6225354B1 (en) 1999-06-21 2001-05-01 Cholesterol Control Laboratories, Inc. High molecular weight primary aliphatic alcohols obtained from beeswax and pharmaceutical use thereof
US20060127449A1 (en) 2003-01-28 2006-06-15 Hargrove James L Method and composition for lowering cholesterol
BRPI0410529B1 (pt) * 2003-04-25 2014-02-18 Composição de aldeído, processo para preparar uma composição de aldeído, composição de álcool e processo para preparar uma composição de álcool
US20050234025A1 (en) 2004-04-20 2005-10-20 Forbes Medi-Tech Inc. Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof
US20060013842A1 (en) 2004-07-15 2006-01-19 Matkin John R Natural mixture of long-chain fatty alcohols and long-chain fatty acids, its obtension from animal and vegetable waxes and its nutraceutical uses
US20070295326A1 (en) 2006-06-07 2007-12-27 Rafael Almagro Method for obtaining long chain aliphatic alcohols and fatty acids from sugar cane mud and related wax esters
BRPI0702137A (pt) * 2007-06-28 2008-09-16 Megh Ind E Com Ltda processo simplificado de obtenção de policosanol a partir de cera de cana-de-açúcar
US20090280199A1 (en) 2007-11-01 2009-11-12 Aaken Laboratories, Inc. Neuroprotective Compositions and Methods of Using Same
CN101491648A (zh) * 2008-01-21 2009-07-29 王法平 一种复方调脂药物
WO2010103549A2 (en) 2009-03-12 2010-09-16 Godavari Biorefineries Ltd A method of obtaining policosanols from natural material
JP5586381B2 (ja) * 2009-10-07 2014-09-10 光洋産業株式会社 ２型糖尿病改善剤及びそれを含有する飲食物
US20110124894A1 (en) * 2009-11-25 2011-05-26 Rafael Almagro Method for obtaining long chain aliphatic alcohols and fatty acids from sugar cane mud and related wax esters
WO2011143587A1 (en) 2010-05-13 2011-11-17 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
WO2020256570A2 (es) * 2019-02-04 2020-12-24 TRICARICO, Giorgio Extracto antioxidante y anticancerigeno de la caña de azucar y su manufactura

Also Published As

Publication number Publication date
CA3224592A1 (en) 2023-01-19
JP2026004429A (ja) 2026-01-14
AU2022309928A1 (en) 2024-02-01
US20240327748A1 (en) 2024-10-03
AU2022309928B2 (en) 2024-12-19
KR20240046718A (ko) 2024-04-09
WO2023284902A1 (es) 2023-01-19
EP4371566A4 (en) 2025-01-22
EP4371566A1 (en) 2024-05-22
JP2024525717A (ja) 2024-07-12
CU20210060A7 (es) 2023-02-13
CN117979984A (zh) 2024-05-03

Similar Documents

Publication Publication Date Title
da Costa et al. Taxane‐induced neurotoxicity: pathophysiology and therapeutic perspectives
Nakano et al. PI3K/AKT signaling mediated by G protein‑coupled receptors is involved in neurodegenerative Parkinson's disease
CR20210552A (es) Inhibidores del inflamasoma nlrp3
DOP2018000273A (es) Compuestos químicos
CY1119817T1 (el) Στερεα μοναδα δοσολογιας διασπωμενη στο στομα που περιεχει συστατικο οιστετρολης
Zhao et al. Hesperidin inhibits ovarian cancer cell viability through endoplasmic reticulum stress signaling pathways
EP2823819A4 (en) PHARMACEUTICAL COMPOSITION USING OLEANOLIC ACIDATE AS ACTIVE AGENT FOR PREVENTING OR TREATING TLR OR IL-6 MEDIATED DISEASES
BR112012014190B8 (pt) composição farmacêutica para o tratamento da síndrome do olho seco
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
SV2010003497A (es) Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
AR066214A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas
AR063096A1 (es) Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
NI202100012A (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
Manayi et al. Methods for the discovery of new anti-aging products–targeted approaches
US10751320B2 (en) Therapeutic agents containing cannabis flavonoid derivatives for the prevention and treatment of neurodegenerative disorders
Ryu et al. Effects of histone acetyltransferase inhibitors on l-DOPA-induced dyskinesia in a murine model of Parkinson’s disease
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
Shin et al. PKCδ knockout mice are protected from para-methoxymethamphetamine-induced mitochondrial stress and associated neurotoxicity in the striatum of mice
BR112023025552A2 (pt) Composições estabilizadas de apilimod e usos das mesmas
CU24732B1 (es) Mezcla de compuestos con altos pesos moleculares, obtenida a partir de la cera de caña de azúcar (saccharum officinarum l.)
Lakshmi et al. Alkoxy glycerol enhanced activity of Oxyresveratrol in Alzheimer’s disease by rescuing Tau protein
Khorsandi et al. Toxic effect of Tropaeolum majus L. leaves on spermatogenesis in mice